ArticleBJU international2025
Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.
Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-world treatment patterns and clinical outcomes in patients with non-muscle invasive bladder cancer: a nationwide evaluation.World journal of urology · 2026Observational
- Article
- Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.Bladder cancer (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess whether the distribution of concomitant carcinoma in situ (CIS; unifocal or multifocal) with papillary non-muscle-invasive bladder cancer (NMIBC) impacts the risk of progression, as concomitant CIS is an established risk factor for progression in papillary NMIBC and commonly used calculators do not make this distinction. PATIENTS AND
methodsIn this multi-institutional retrospective cohort study from both academic and community hospitals, clinicopathological data were collected from patients with pTa/pT1 NMIBC treated from 2005 to 2022. Unifocal concomitant CIS was defined as CIS present in only one specimen (i.e., papillary disease with CIS at the tumour base or isolated CIS in one specimen). Multifocal concomitant CIS was characterised by CIS in multiple specimens. Progression was defined as the development of muscle-invasive or metastatic disease. Fine-Gray regression was performed to identify progression-associated factors, using all-cause mortality as a competing risk.
resultsAmong 2923 patients, 383 (13%) progressed over a median (interquartile range) follow-up of 5.1 (3.0-8.5) years. Concomitant CIS was found in 327 patients (11%), with 233 and 94 harbouring unifocal and multifocal CIS, respectively. Recurrent tumours, T1 stage, high-grade disease, multifocal CIS, and multiple tumours were independently associated with increased progression risk (all P < 0.05). Among patients with concomitant CIS, multifocal CIS remained a significant prognosticator (sub-distribution hazard ratio 1.90, 95% confidence interval 1.18-3.05; P = 0.008) adjusting for age, sex, tumour history, stage, grade, number of tumours, tumour diameter, and Bacillus Calmette-Guérin treatment.
conclusionsPapillary NMIBC progression risk varies with concomitant CIS distribution. Only multifocal concomitant CIS is a risk factor for progression in patients with T1 NMIBC. If validated in further studies, risk calculators should consider including this CIS distinction. Submitting separate specimens at the time of transurethral resection, as recommended by guidelines, should be encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.